Wilczok Dominika, Zhavoronkov Alex
Duke University, Durham, North Carolina, USA.
Insilico Medicine US Inc, Cambridge, Massachusetts, USA.
Clin Pharmacol Ther. 2025 Apr;117(4):887-890. doi: 10.1002/cpt.3542. Epub 2024 Dec 25.
Since the deep learning revolution of the early 2010s, significant efforts and billions of dollars have been invested in applying artificial intelligence (AI) to drug discovery and development (AIDD). However, despite high expectations, few AI-discovered or AI-designed drugs have entered human clinical trials, and none have achieved clinical approval. In this perspective, we examine the challenges impeding progress and highlight opportunities to harness AI's potential in transforming drug discovery and development.
自21世纪10年代初的深度学习革命以来，人们在将人工智能（AI）应用于药物发现与开发（AIDD）方面投入了大量精力和数十亿美元。然而，尽管寄予厚望，但很少有通过人工智能发现或设计的药物进入人体临床试验，且无一获得临床批准。从这个角度来看，我们审视了阻碍进展的挑战，并强调了利用人工智能潜力来变革药物发现与开发的机遇。
